Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cardiac Assist Technologies Inc.

Latest From Cardiac Assist Technologies Inc.

TCT 2017: Fewer Stents Are Better Than More For Initial AMI-With-Shock Treatment

Results of the CULPRIT-SHOCK trial presented at the Transcatheter Cardiovascular Therapeutics conference in Denver confirm that patients with acute myocardial infarction complicated by cardiogenic shock are better off treated with culprit-lesion-only percutaneous coronary intervention rather than multivessel stenting, which is currently recommended in the European guidelines.

Cardiology Clinical Trials

Experts Call For More Clinical Trials Of Percutaneous Circulatory Devices

A new multi-society clinical expert consensus statement on percutaneous mechanical circulatory support is intended to help physicians select devices for the patients who are most likely to benefit, but the authors identify several questions about the devices that need to be addressed in future clinical studies.

Medical Device

CardioClasp Inc.

David Melvin, MD, a cardiac transplant surgeon who started and built the heart transplant program at the University Hospital, Cincinnati, took a sabbatical in 1991 to research and invent devices for congestive heart failure. His efforts resulted in several patented devices, among them the CardioClasp. CardioClasp is a simple, passive device that is designed to surround a patient's failing heart, to geometrically remodel it and correct for the pathological increase in size that congestive heart failure causes.

Medical Device

The Bridge Across Forever: Devices for CHF

A new generation of miniature, totally implantable devices for end-stage congestive heart failure promises to return patients to normal lives. If the implantable ventricular assist devices can function reliably for many years, they may offer patients an alternative to heart transplantation and even arrest the progression of the diseases at earlier stages.

Medical Device Platform Technologies
See All

Company Information

  • Industry
  • Medical Devices